2016

Eureka’s manuscript on targeting alpha-fetoprotein (AFP) with a CAR T cell therapy for liver cancer is published in Clinical Cancer Research

November 29, 2016

Eureka’s manuscript on targeting alpha-fetoprotein (AFP) with a CAR T cell therapy for the treatment of liver cancer is published in Clinical Cancer Research on August

Multiple Myeloma Partnership with Juno Therapeutics for Developing CAR T Cell Immunotherapy Against Multiple Novel Targets

August 4, 2016

EMERYVILLE, Calif. & NEW YORK & SEATTLE, Aug 4th, 2016 – Eureka Therapeutics, Inc. and Memorial Sloan Kettering Cancer Center(MSK) announced today an exclusive license agreement

Eureka Therapeutics Announces Exclusive License Agreement between Memorial Sloan Kettering Cancer Center and Juno Therapeutics for Use of a Novel, Fully-Human MUC16 Binder in CAR T Cell Immunotherapy

January 7, 2016

EMERYVILLE, CA, Jan. 7th, 2016 – Eureka Therapeutics, Inc. announced today that Memorial Sloan Kettering Cancer Center and Juno Therapeutics, Inc. (Nasdaq: JUNO) have entered into